Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

NCT03040999
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Not applicable Interventional

The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients

NCT04275830
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System, Stress, Mood, Psychological Distress, Emotion Regulation, Communication Research, Narrative
Interventions
Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 23, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)

NCT07089953
View directory record Official record
Conditions
Communication Skills, Professionalism, Randomized Controlled Trial, Perception
Interventions
Questionnaire, Video
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

NCT01984892
View directory record Official record
Conditions
Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions
Poly-ICLC
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
14 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 9:14 PM EDT
Recruiting Phase 2 Interventional

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Talquetamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Priming and Patient Reported Outcome Measures

NCT05229016
View directory record Official record
Conditions
Patient Participation, PROM
Interventions
Reflection on health-related experiences
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

NCT02380443
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
AlloStim, Cryoablation
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 9:14 PM EDT
Not yet recruiting Not applicable Interventional

PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)

NCT07638150
View directory record Official record
Conditions
Breast Cancer
Interventions
Mediterranean Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

NCT02151344
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

NCT00258895
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis
Interventions
DAPTACEL®: DTaP
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
649 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
22
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 23, 2026, 9:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma

NCT07759102
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim, Fludarabine, Granulocyte Colony-Stimulating Factor, Thiotepa
Biological · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Not listed Phase 1 Interventional

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00002616
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Up to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 9:14 PM EDT
Active, not recruiting Phase 1 Interventional

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

NCT02287428
View directory record Official record
Conditions
Glioblastoma
Interventions
Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab, Temozolomide, Poly-ICLC
Radiation · Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
La Jolla, California • Shreveport, Louisiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Terminated Not applicable Interventional

Prime Time for Superficial Femoral Artery (SFA) - The SFA Study

NCT00902317
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Cryoplasty (PolarCath peripheral balloon catheter), Laser Angioplasty (Spectranetics), SilverHawk Atherectomy, Viabahn Endograft, Angioplasty/Stent (Guidant "Absolute" stent)
Procedure · Device
Lead sponsor
Arizona Heart Institute
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2009 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

Pneumococcal Vaccines in Patients With Asthma

NCT03260790
View directory record Official record
Conditions
Asthma
Interventions
PCV13, PPSV23
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754
View directory record Official record
Conditions
Malaria
Interventions
D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 23, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study

NCT07567053
View directory record Official record
Conditions
Cerebral Palsy, Typically Developing Children
Interventions
MRI, HD-EEG Recording, rTMS
Device
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
6 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Active, not recruiting Not applicable Interventional

Celtra Quatro Crown Study

NCT04604301
View directory record Official record
Conditions
Fractured Tooth, Decayed Tooth, Unsatisfactory Restoration of Tooth
Interventions
Celtra Quatro
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 9:14 PM EDT
Terminated Phase 1 Interventional

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

NCT02454270
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

NCT01023711
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 23, 2026, 9:14 PM EDT
Completed Phase 1Phase 2 Interventional

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

NCT00861107
View directory record Official record
Conditions
Metastatic Cancer
Interventions
AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 9:14 PM EDT